Leiden, Utrecht September 2019 – MIMETAS and Hubrecht Organoid Technology (HUB) announce that they entered into a strategic collaboration to market organoid models on a chip. The agreement includes a license to MIMETAS to market HUB Organoids™ in an assay ready format, as well as a collaborative effort to develop disease-specific models.


Have any questions?

contact us